Overview

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Status:
Not yet recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

The study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis. The study will also investigate if brodalumab affects development of vaccination-induced immune responses. The study will run over 62-64 weeks (including screening, treatment, and safety follow-up) for each participant, but with the primary endpoint measured at Week 12.

Phase:

Phase 3

Details

Lead Sponsor:

LEO Pharma

Treatments:

Antibodies, Monoclonal
Brodalumab
Ustekinumab